- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05000307
Co-Sér: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection (Coser)
Co-Sér: Serological Analysis and Viral Neutralization in People With a Documented COVID-19
In light of the current coronavirus disease 2019 (COVID-19) pandemic, the investigators want to better study the immunological characteristics of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) infections in adults. The investigators invite volunteers to participate in a clinical study to better understand what happens after an infection with SARS-CoV2. By collecting and analysing blood samples of people that were infected, the investigators want to evaluate whether or not the participants had an adaptive immune response with the producting of immunoglobulin. The investigators will evaluate the quality of the antibodies and their neutralising capacity. In a selected patient group with strong antibody response, the investigators will try to reproduce them in the lab after the collection of a larger blood sample (max 72 mL) of, in case of insufficient B-cells, a leucapheresis (after consent of the patient). These antibodies can be used in clinical trials to evaluate whether the investigators can cure patients faster or prevent disease by the utilisation of these antibodies.
Aside from the aforementioned information the investigators will also collect clinical data such as: demographic information, medical history, routine lab results, radiographic imaging and medication use.
After the completion of the study, the samples will be stored for 30 years with consent of the participants.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgium, 9000
- Ghent university Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Evidence of prior COVID-19 infection, documented by polymerase chain reaction (PCR) or antibody testing (IgG based)
Exclusion Criteria:
- Known pregnancy at the time of screening
- Patient is on immunosuppressive therapy or was treated with immunosuppressive therapy during the last 6 months
- Inability to give informed consent or absence of legal representative who can give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Volunteers, infected with COVID-19
|
Analysing blood samples for the presence of antibody against SARS-CoV2.
When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Neutralising capacity of naturally produced antibodies against SARS-CoV2
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Linos Vandekerckhove, MD PhD, PI
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BC-08071
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV Infection
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
Chulalongkorn UniversityRamathibodi Hospital; Ministry of Health, Thailand; The Government Pharmaceutical... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS CoV 2 InfectionThailand
-
The Board of MedicineApollo Neuroscience, Inc.RecruitingPost-acute Sequelae of SARS-COV-2 InfectionUnited States
-
Imam Abdulrahman Bin Faisal UniversityDammam Medical Complex; Institute for Research and medical consultations (IRMC)UnknownHospitalized Patients | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) | Laboratory-confirmed SARS-CoV 2 InfectionSaudi Arabia
-
Sophia Koo, M.D.Massachusetts General Hospital; GlaxoSmithKline; Dana-Farber Cancer InstituteActive, not recruitingSARS CoV 2 InfectionUnited States
-
Banaras Hindu UniversityCompleted
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
Rutgers, The State University of New JerseyNational Institute of Dental and Craniofacial Research (NIDCR)Completed
-
Ospedale Generale Di Zona Moriggia-PelasciniCompletedCOVID-19 | Sars-CoV-2 InfectionItaly
Clinical Trials on Blood sample
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Centre Hospitalier Universitaire de NīmesNot yet recruitingNarcolepsy Type 1 | Bacterial TranslocationFrance
-
The First Affiliated Hospital of Soochow UniversityRecruitingGraft Vs Host DiseaseChina
-
Assistance Publique - Hôpitaux de ParisRecruitingClassification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) (CILLICORIRCM)Ciliopathies | Bardet-Biedl Syndrome | Nephronophthisis | Senior-Loken Syndrome | Joubert Syndrome | Jeune SyndromeFrance
-
Centre Hospitalier Universitaire DijonRecruiting
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHeart FailureUnited States
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, France; ANRS, Emerging...Completed
-
GlaxoSmithKlineCompletedInfections, StreptococcalBelgium
-
Meir Medical CenterCompleted